NCT03188432View on ClinicalTrials.gov

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

January 31, 2024

Study Completion Date

February 8, 2024

Conditions

Stage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Primary Peritoneal CancerStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal Cancer

Interventions

DRUG

Carboplatin

Given IV and IP

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Cytoreductive Surgery

Undergo CRS

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03188432 - Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter